Member Info for Hikikomori

Increase it

Anything to substantiate those ISA claims Drutor?

Because that sounds like bu11****

It’s a bit disingenuous to suggest it’s been another week of no news, considering there was a company update via RNS on Monday.

And yes, I am well aware this was not regarding CART, before you pipe back up.

Mr I,

Not sure how I gave you the impression I believed stu had bought in and was attempting to pump the price? Apologies for any confusion.

I don’t personally believe he had bought in, which to be fair is something he stated in his posts. I have no reason to disbelieve him. After all, had he wanted to boost the SP he would surely have been better off stating he had invested, would he not?

I don’t really care either way really, as I trust him about as far as I can throw a wet mattress.

As for me, I can assure you there is no stress here. I understand that junior pharma is high risk/high reward, but I have always been comfortable with my investment.

I am pleased you finally had a conversation with Hemo.

Agree to an extent IslandGirl, but outside of the company website this is the first place many potential investors will visit.

Whilst true that one individual poster is unlikely to have any impact on the SP, a sea of negativity from unhappy SH’s will definitely be off putting to any prospective buyer, who is unlikely to want to invest their capital here if that’s all they see.

The content of the next RNS is what is important, not the timing. Until then there is nothing much to see here, and endless speculation of when news is coming is unhelpful.

By hype I was meaning people talking it up, as opposed to driving it up, a bit like you were doing recently at HE1 by suggesting it was going to go up from just over 1p to 10p within a week or two.

Much more volume over there at HE1 of course, but clearly half of the trades there were also sells, just like here.

Based on many posts over the last week from various contributors on this board, there appears to be a lot of confirmation bias taking place.

Stu has expertly fed into this with very cleverly crafted emails which have been taken by many as showing a positive change of sentiment.

He has done so by claiming he expects to see two RNS’ from Hemo. It’s worth noting, that by his own words he has drawn these conclusions from the timing and wording of previous RNS announcements. That is not to say he actually believes this to be the case. I wouldn’t care to guess, but there is evidence in some of his posts to support the fact he isn’t as optimistic as some have taken him to be.

I pose the question, if news doesn’t come this week, or even next, what will the sentiment be from those here who are buying into the hype that news is definitely imminent?

We all know that posters like Mr India can very quickly turn this board toxic. He changes his opinion on Hemo, and its outlook, more often than some here change their underwear.

Perhaps turning this board into a toxic swamp is a scenario that some here would take pleasure in seeing, or perhaps, dare I say, causing.

I sincerely hope for good news soon, but I will be patient and await official news via RNS, and I refuse to get carried away by speculation of when this will arrive in the meantime.

I suggest that some others here might do the same.

Thanks for your contributions today HK,

It’s always better to respond to Stu with science and facts, rather than simply arguing with him about nonsense, which is exactly what he wants people to do.

Have a good weekend.

That’s due to an uncrossing trade that went through at 1.4p after the end of trading.

It will be back to trading around 1.3p first thing tomorrow morning.

Whilst it hasn’t had much impact on volume or share price today, this mornings RNS is welcome news.

Given the work they have been doing with CBR in US Government facilities, the fact they have been successful in competing for a presentation slot at this US Government Chemical and Biological Defence Conference is a good indicator that testing so far has been promising.

It’s hard to see the negatives in this RNS, though I am sure there will be some of the usual suspects here who will try.

To be honest swazers, you have entered this BB portraying yourself as some sort of expert in Hemo, yet having watched your analysis the first thing you did was talk about AIM.

Granted, you did state shortly after this was an oversight on your part, but you kind of lost me straight away.

I think your attitude, which some will perceive as arrogance, has probably rubbed a few long term holders up the wrong way.

You also seem intent on picking fights with people who seemingly want the same outcome, which is odd behaviour.

Some of the people you have directed unfriendly comments toward have probably forgotten more about Hemo than you will ever even know about the company.

Anyway, good luck with your platform and your charts. It’s not for me.

Micky, the RNS from yesterday can be read via this link.

https://www.londonstockexchange.com/news-article/HEMO/macrophage-directed-therapies-summit-presentation/16589824

Anyone can subscribe to company RNS alerts directly from the London Stock Exchange, which is a free service.

If you want to ensure you get news in real time, I would suggest you set an alert up. That way, you are not subject to relying on this website for the most up to date developments, which as evidenced yesterday, is not completely reliable.

Even a placing at 2p wouldn’t generate enough cash to sustain 2 years JRDC, let alone at 1p as you suggest, so it’s a complete non starter.

You should stop pushing the idea.

Pwil,

It’s been long established that trials would not begin until 2H of 2024, so not sure why it should come as such a surprise to you that they haven’t begun prior to that.

Secondly, what sort of CEO would talk down his own company on LSE the way Stu does?

You are either an idiot, or someone with an agenda to drive down the SP.

hi stu,

assuming there’s a 7% chance of success, as you state, would it be reasonable to assume that success would see the share price rise to 15 times his average (let’s guess around 2.5p by using his 150% profit claim)?

so working it out on the back of a *** packet, that would mean a share price of 37.5p as a ball mark figure, making the market cap somewhere around 500 million.

i think that is probably undervalued for an approved cart treatment (not to mention their other product candidates).

so the answer to your question is that yes, it still has positive expected value if the above is all correct, assuming you are willing to lose your entire investment of course (the number one rule when investing).

junior pharma is always a huge gamble, but for me the potential returns still greatly outweigh the risk.

aimo

Digittt, well said.

Probably the most considered post on here in what feels like weeks.

Best wishes for a full recovery for your son BigBone.

Totally agree ConsDoms,

There’s enough promise here to continue to hold, particularly at this low share price.

Junior pharma at development stage comes with plenty of risk, but the rewards can be huge. If the risk/reward ratio at these levels isn’t enough for people to stick around, they should probably never have invested here in the first place to be honest.

It goes by the bid and the ask prices at the time of the trade, then depending on which of those prices the trade is closer to, that’s how it shows it.

Obviously it doesn’t always get it correct.

Well I’ll still be here, perhaps with a few less shares, but I’ll definitely still hold a good few.

If CBR can deliver a fraction of what it promises it might, 1000% will seem like chicken feed.

I absolutely intend to make sure I’m still in the game to find out.

Have a good weekend all.